Latest Regulatory Challenges News

Macquarie Group Limited reported a 5% increase in FY25 profit to A$3.715 billion, declaring a higher dividend and announcing a key CFO transition. The group also outlined a strategic divestment and cautious outlook for FY26.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

The Virginia Supreme Court has affirmed the State Corporation Commission’s decision to deny a toll rate increase for the Dulles Greenway, owned by Atlas Arteria. Meanwhile, a related federal case alleging constitutional violations will now proceed.

G8 Education faces ASX scrutiny over its handling of sensitive information about a former employee, with the regulator questioning the company’s disclosure practices despite GEM’s insistence of compliance.

The Takeovers Panel has decided not to proceed with an application challenging Keybridge Capital’s board decisions amid Yowie Group’s takeover bid, citing prior rulings and no unacceptable circumstances.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

Kinatico Limited has reported a record FY25 revenue of $32.1 million, driven by a remarkable 54% increase in SaaS revenue and a cash-positive year despite significant technology investments.

C29 Metals has exited its Kazakhstan operations to focus on advancing its Mayfield Copper & Gold Project in Queensland, securing a three-year exploration license extension and confirming strong geological potential.

The Takeovers Panel has declared unacceptable circumstances in Emu NL’s recent shareholder meeting, citing a controversial share placement and proxy voting issues that clouded the election outcome and board control.

ALS Limited reported a robust FY25 with 16% revenue growth to AUD 3 billion, underpinned by strong organic expansion and key acquisitions. Despite slight NPAT decline, the company advances its sustainability agenda and invests in global lab upgrades.

PointsBet shareholders have voted in favour of the proposed $1.20 per share acquisition by MIXI, Inc, marking a significant premium and clearing a key hurdle ahead of court approval.